HER2 therapy

Jan 02, 2023

ENHERTU is an antibody-drug conjugate composed of an anti-HER2 antibody and a cytotoxic topoisomerase I inhibitor. Three components make up this ADC:  A topoisomerase inhibitor that is covalently linked to, Humanized anti-HER2 IgG1 monoclonal antibody (mAb) via, Tetrapeptide-based cleavable linker Rec...

Jan 11, 2019

Breast cancer develops when breast tissue cells grow abnormally and multiply. In essence, the hormones-- estrogen and progesterone-- and excess levels of human epidermal growth factor receptor 2 (HER2) protein are the known drivers of breast cancer. By testing samples of breast cancer tissue for hormone receptors a...